Advancing gastric cancer treatment: A comprehensive review of hyperthermic intraperitoneal chemotherapy’s role and outcomes

Table 4 Therapeutic use of hyperthermic intraperitoneal chemotherapy, controlled trials: Treatments and outcomes (all patients received neoadjuvant systemic chemotherapy)

Year	Ref./trail	Patient cohort	S. Cht protocol	S. Cht cycles	N-HIPEC	Laparoscopic N-HIPEC	N-HIPEC protocol	N-HIPEC cycles	Convertion to surgery	T-HIPEC protocol	NIPEC	Adjuvant HIPEC bed site	OS media	1 year OS	2 years OS	3 years OS	Relapse-free survival media (month)
2020	Blum Murphy et al[31]	27	5-FU/OX (n = 24%-89%), 5-FU/OX/Pacli (n = 3%-11%)	9 (range 4-24)	Yes	27 patients	Mitomycin C (30 mg) + cisplatin (200 mg). Paclitaxel (dosing was started at 20 mg/m2 and sequentially increased up to 60 mg/m2)	1	CRS-H (6/27), CRS-A (1/27) 25.9%	ND	No	No	ND	73.9%	58.1%	ND	ND
2020	Yu et al[30]	38	Pacli + S1 (Transtuzumab added in HER-2+)	4	Yes	No	Paclitaxel (75 mg/m2) for 60 minutes	2	18 (47.4%)	Paclitaxel (75 mg/m2) for 60 minutes	No	Yes (twice within 72 hours after CRS)	Conversion therapy group 21.1 months	63.2%	47.40%	ND	ND
2020	Koemans/PERISCOPE 1	25	Epirubicin + cisplatin + capecitabin (n = 10), docetaxel + oxaliplatin + capecitabin (n = 7), capecitabin + oxaliplatin (n = 3), 5-FU/OX (n = 2), capecitabin + oxaliplatin (n = 3), Transtuzumab added in HER-2+	3	No	No	No	No	No	Oxaliplatin (460 mg/sm) for 30 minutes	Docetaxel for 90 minutes in a dose-level escalation scheme (0, 50, 75 mg/m2)	No	15 months	ND	ND	ND	12 months
2021	Badgwell et al[35]	20	5-FU+ OX (n = 17/20), Triplet therapy (n = 3/20)	< 8 (20%), 8-10 (75%), > 10 (5%)	Yes	20 patients	Mitomycin C (30 mg) + cisplatin (200 mg) for 60 minutes	2 (n = 5/20), 1 (n = 15/20)	No	Mitomycin C (30 mg) + cisplatin (200 mg) for 60 minutes	No	No	22.1 months	90%	50%	28%	ND
2023	Green et al[34]	41	Fluoruracil, leucovorin, oxaliplatin (56%), fluorouracil, leucovorin, oxaliplatin, and docetaxel (24%), radiotherapy (17%)	ND	Yes	23 patients	Cisplatin (90 mg/mq) + mitomycin C (10 mg/mq or 30 mg/mq) for 60 minutes	1 or 2	No	Cisplatin (90 mg/mq) + mitomycin C (10 mg/mq) for 60 minutes	No	No	24.9 months	ND	ND	25%	7.4 months

CRS: Cytoreductive surgery; HER-2: Human epidermal growth factor receptor 2; HIPEC: Hyperthermic intraperitoneal chemotherapy; ND: Not declared; OS: Overall survival; OX: Oxaliplatin; S. Cht: Systemic chemotherapy; 5-FU: 5-fluorouracil.